Opinion

Video

Challenges in Risk Assessment and Biomarkers in Treatment Recommendations

Author(s):

Benjamin H. Lowentritt, MD, FACS,Brian Richardson, MD

The panelists examine the challenges and limitations they've faced when using the Gleason score for risk assessment in prostate cancer patients, while also highlighting how biomarker testing has informed and guided their treatment strategies.

Video content above is prompted by the following question:

  • What are some challenges or limitations you have encountered when using the Gleason score when assessing risk in your prostate cancer patients?
  • In your clinical experience, have biomarkers guided your treatment recommendations? If so which one(s)?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Ruben Olivares, MD, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Related Content
Man talking with doctor | Image Credit: © Chinnapong - stock.adobe.com
July 7th 2025

FDA and EMA authorize phase 3 trial of masitinib for mCRPC

Benjamin P. Saylor
For the trial, a biomarker will be utilized to aid in patient selection for the treatment.
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
Regulatory recap: FDA approvals in urology from the first half of 2025
July 4th 2025

Regulatory recap: FDA approvals in urology from the first half of 2025

Hannah Clarke
Take a look through all the regulatory milestones in urology from the first half of the 2025.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
FDA logo
July 3rd 2025

FDA news recap in urology for Q2 2025

Hannah Clarke Benjamin P. Saylor Jason M. Broderick
Here’s a look back at notable news between April and June 2025.
Enrollment begins in phase 2 trial of opaganib plus darolutamide in mCRPC
July 2nd 2025

Enrollment begins in phase 2 trial of opaganib plus darolutamide in mCRPC

Hannah Clarke
The study will utilize the companion lipid biomarker test, PCPro, to identify patients who may benefit from the addition of opaganib to darolutamide.
© 2025 MJH Life Sciences

All rights reserved.